Ceribell, Inc. (CBLL) Stock Price & Analysis
Ceribell, Inc. (CBLL) rose 3.87% to USD 16.91 as of July 26, 2026 at 09:42 UTC, according to Nexqual real-time market data.
CBLL last closed at USD 16.28; the session ranged USD 16.1–17.19 on volume of 347,127 shares. Market capitalization is $641.61M, with a 52-week range of USD 10.85–24.33 (NMS). Source: Nexqual, July 26, 2026 at 09:42 UTC.
Key Statistics (as of July 26, 2026 at 09:42 UTC)
| Price | USD 16.91 |
|---|---|
| Change | ▲ 3.87% (up) |
| Previous Close | USD 16.28 |
| Open | USD 16.4 |
| Day Range | USD 16.1 – 17.19 |
| 52-Week Range | USD 10.85 – 24.33 |
| Volume | 347,127 shares |
| Market Cap | $641.61M |
| Exchange | NMS |
Technical Analysis (CBLL)
Nexqual's technical model rates CBLL "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 09:42 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.3 (neutral) |
| vs SMA50 | Below (USD 18.43) |
| MACD | -0.46 (negative) |
Analyst Ratings (CBLL)
Wall Street analysts rate CBLL "Strong Buy" based on 7 analysts, with a mean price target of USD 26.86 (range USD 24–32), per Nexqual as of July 26, 2026 at 09:42 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 26.86 |
| High Target | USD 32 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CBLL)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.46 |
| Revenue Estimate | $27.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.38 vs est -0.39 ▲ beat |
| 2025-12-31 | USD -0.36 vs est -0.41 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.41 ▲ beat |
| 2025-06-30 | USD -0.38 vs est -0.4 ▲ beat |
Source: Nexqual, July 26, 2026 at 09:42 UTC.
Financials & Fundamentals (CBLL)
| Total Revenue | $95.07M |
|---|---|
| Revenue Growth (YoY) | +29.30% |
| Gross Margin | +87.72% |
| Operating Margin | -78.30% |
| Profit Margin | -63.51% |
| ROE | -37.53% |
| Debt / Equity | 15.71 |
| Current Ratio | 10.44 |
| Total Cash | $141.18M |
| Total Debt | $22.12M |
| Free Cash Flow | $-29.33M |
Source: Nexqual, July 26, 2026 at 09:42 UTC.
Financial Health Score (CBLL)
Nexqual rates Ceribell, Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 09:42 UTC.
| Growth | Strong — Revenue +36% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 88%, operating -78% |
| Balance Sheet | Strong — $141M cash vs $22M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$29M, burning cash |
| Efficiency | Critical — ROE -38%, ROA -20.7% |
Ownership (CBLL)
| Insider Ownership | +12.79% |
|---|---|
| Institutional Ownership | +86.87% |
| Shares Outstanding | 37.94M |
| Float | 26.06M |
| Short % of Float | +7.51% |
Source: Nexqual, July 26, 2026 at 09:42 UTC.
Leadership (CBLL)
Ceribell, Inc. is led by Xingjuan Chao (age 44), Co-Founder, President, CEO & Director, per Nexqual as of July 26, 2026 at 09:42 UTC.
| Co-Founder, President, CEO & Director | Xingjuan Chao (age 44) |
|---|---|
| Co-Founder, Chief Medical Advisor & Director | Josef Parvizi (age 56) |
| Chief Financial Officer | Scott Blumberg |
| Chief Technology Officer | Raymond Woo (age 42) |
| Senior Vice President of Operations | Dan Rogy |
Major Backers & Investors (CBLL)
Notable institutional backers of Ceribell, Inc. include FMR, LLC, Fidelity, TPG GP A, LLC, according to Nexqual as of July 26, 2026 at 09:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.78% |
| Fidelity | 11.68% |
| TPG GP A, LLC | 10.46% |
| Red Tree Management, LLC | 5.81% |
| Federated Hermes, Inc. | 4.96% |
| KCM Capital Inc | 3.69% |
| Franklin Resources, Inc. | 2.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.48% |
| Vanguard Group | 5.3% |
| BNY Mellon | 4.19% |
Source: Nexqual, July 26, 2026 at 09:42 UTC.
From Ceribell, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- CeriBell, Inc. operates as a medical technology company in the United States.
- It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
- The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm.
- In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UPB | Upstream Bio, Inc. | USD 6.41 | ▼ 2.73% |
| BBNX | Beta Bionics, Inc. | USD 15.85 | ▼ 2.82% |
| KMTS | Kestra Medical Technologies, Lt | USD 21.06 | ▲ 0.81% |
| BCAX | Bicara Therapeutics Inc. | USD 27.02 | ▼ 3.36% |
| MBX | MBX Biosciences, Inc. | USD 62 | ▲ 6.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 09:42 UTC. This page is informational and not investment advice.